Is Medication Overuse Drug Specific or Not? Data from a Review of Published Literature and from an Original Study on Italian MOH Patients
- 119 Downloads
Purpose of Review
The aim is twofold. First, to give an insight on the role exerted by different classes of drugs in favouring migraine chronification. Second, to explore the relationship between type and amount of overused medications and history of previous withdrawal treatment and of frequent relapses.
All drug classes were found to favour migraine chronification. No data are available for the association with relapses into CM-MOH. Our clinical study shows that patients who underwent previous withdrawal treatments were more likely to be overusers of multiple drug classes and overuse higher amounts of symptomatic medications, particularly, indomethacin, eletriptan and tramadol. Frequent relapsers were more likely to be overusers of opioids or ergotamine and caffeine derivates or of multiple classes, particularly acetylsalicylic acid and ergotamine/caffeine derivates.
The joint results our review and clinical study do not seem to support the idea that MOH is drug-specific: rather, it points out that all drug classes may induce migraine chronification. Those drugs which are at higher risk of overuse are among those preferred by the “worst” patients, i.e. those who needed one or more withdrawal treatments for MOH. Our results reinforce the clinical impression that patients with CM and MOH, and particularly the most difficult to treat for their poor response to withdrawal treatments, are characterised by a particular drive towards the consumption of “whatever is likely to be perceived to provide some relief”, despite these drugs that are perceived as “more powerful”, are often indicated as second- or third-line medications.
KeywordsChronic migraine Medication-overuse headache Triptans Anti-inflammatory drugs Opioids Withdrawal
Compliance with Ethical Standards
The protocol was approved by the Besta Institute Ethical Committee (protocol no. 379/2015).
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.International Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd ed. Cephalalgia. 2018;38:1–211.Google Scholar
- 2.•• Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48(8):1157–68. This is one of the first and most important studies addressing the risk of chronification connected to the use of acute medications. CrossRefPubMedGoogle Scholar
- 6.Bendtsen L, Munksgaard S, Tassorelli C, Nappi G, Katsarava Z, Lainez M, et al. Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia. 2014;34:426–33.CrossRefPubMedGoogle Scholar
- 16.Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, et al. International Headache Society Clinical Trials Standing Committee. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018;38(5):815–32.CrossRefPubMedGoogle Scholar
- 17.• Katsarava Z, Muessig M, Dzagnidze A, Fritsche G, Diener HC, Limmroth V. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia. 2005;25:12–5. This is the first study addressing long-term relapse rate and providing data on the "protective" effect of triptans on relapse rate into MOH. CrossRefPubMedGoogle Scholar
- 18.• Katsarava Z, Limmroth V, Finke M, Diener HC, Fritsche G. Rates and predictors for relapse in medication overuse headache: a 1-year prospective study. Neurology. 2003;60:1682–3. This is one of the the first study addressing medium-term relapse rate and providing data on the "protective" effect of triptans on relapse rate into MOH. CrossRefPubMedGoogle Scholar
- 22.Raggi A, Giovannetti AM, Leonardi M, Sansone E, Schiavolin S, Curone M, et al. Predictors of 12-months relapse after withdrawal treatment in hospitalized patients with chronic migraine associated with medication overuse: a longitudinal observational study. Headache. 2017;57:60–70.CrossRefPubMedGoogle Scholar
- 28.Scaratti C, Covelli V, Guastafierro E, Leonardi M, Grazzi L, Rizzoli PB, et al. A qualitative study on patients with chronic migraine with medication overuse headache: comparing frequent and non-frequent relapsers. Headache. 2018 ( E-Pub ahead of print. https://doi.org/10.1111/head.13385).
- 30.•• Lipton RB, Serrano D, Nicholson RA, Buse DC, Runken MC, Reed ML. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2013;53(10):1548–63. This is a population study that addressed the risk of chronification connected to the use of triptans. CrossRefPubMedGoogle Scholar
- 38.Sandrini G, Cerbo R, Del Bene E, Ferrari A, Genco S, Grazioli I, et al. Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomized, parallel group, multicentre study. Int J Clin Pract. 2007;61(8):1256–69.CrossRefPubMedPubMedCentralGoogle Scholar
- 39.• Scher AI1, Lipton RB, Stewart WF, Bigal M. Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study. Cephalalgia. 2010;30(3):321–8. This is one of the most important population studies investigating the pattern of consumption of acute medications among CDH sufferers. CrossRefPubMedGoogle Scholar
- 40.Ferrari A, Savino G, Gallesi D, Pinetti D, Bertolini A, Sances G, et al. Effect of overuse of the antimigraine combination of indomethacin, prochlorperazine and caffeine (IPC) on the disposition of its components in chronic headache patients. Pharmacol Res. 2006;54(2):142–9.CrossRefPubMedGoogle Scholar
- 45.Weissman-Fogel I, Sprecher E, Granovsky Y, Yarnitsky M. Repeated noxious stimulation of the skin enhances cutaneous pain perception of migraine patients in-between attacks: clinical evidence for continuous sub-threshold increase in membrane excitability of central trigeminovascular neurons. Pain. 2003;104:693–700.CrossRefPubMedGoogle Scholar
- 48.Mathur VA, Moayedi M, Keaser ML, Khan SA, Hubbard CS, Goyal M, et al. High frequency migraine is associated with lower acute pain sensitivity and abnormal insula activity related to migraine pain intensity, attack frequency, and pain catastrophizing. Front Hum Neurosci. 2016;10:489.CrossRefPubMedPubMedCentralGoogle Scholar
- 62.Lipton RB. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles. Headache. 1997;37(Suppl 1):33–41.Google Scholar